Long-term clinical outcomes and factors predictive of relapse after 5-aminosalicylate or sulfasalazine therapy in patients with intestinal behcet disease

Journal of Clinical Gastroenterology

Volumn 46, Issue 5, 2012, Pages e38-e45

  Jung, Yoon Suk ^a   Hong, Sung Pil ^a   Kim, Tae Il ^a   Kim, Won Ho ^a   Cheon, Jae Hee ^a  

^a Yonsei University College of Medicine   (South Korea)

Author keywords

5 aminosalicylic acid; Clinical relapse; Intestinal Behcet disease; Sulfasalazine

Indexed keywords

C REACTIVE PROTEIN; MESALAZINE; SALAZOSULFAPYRIDINE;

ADULT; BEHCET DISEASE; CLINICAL ASSESSMENT; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE ACTIVITY; FEMALE; HIGH RISK PATIENT; HUMAN; KAPLAN MEIER METHOD; LOG RANK TEST; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; OUTCOME ASSESSMENT; PREDICTIVE VALIDITY; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; RELAPSE; REMISSION; REVIEW; RISK FACTOR; SCORING SYSTEM; UNIVARIATE ANALYSIS;

ADULT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BEHCET SYNDROME; C-REACTIVE PROTEIN; FEMALE; HUMANS; INTESTINAL DISEASES; MALE; MESALAMINE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RECURRENCE; SULFASALAZINE; TIME FACTORS; TREATMENT OUTCOME;

EID: 84862830283     PISSN: 01920790     EISSN: 15392031     Source Type: Journal    
DOI: 10.1097/MCG.0b013e3182431d56     Document Type: Article

References (40)

1. Sakane T, Takeno M, Suzuki N, et al. Behcet’s disease. N Engl J Med. 1999;341:1284-1291
2. O’Duffy JD. Behcet’s disease. Curr Opin Rheumatol. 1994;6:39-43
3. Cheon JH, Kim ES, Shin SJ, et al. Development and validation of novel diagnostic criteria for intestinal Behcet’s disease in Korean patients with ileocolonic ulcers. Am J Gastroenterol. 2009;104:2492-2499
4. Kobayashi K, Ueno F, Bito S, et al. Development of consensus statements for the diagnosis and management of intestinal Behcet’s disease using a modified Delphi approach. J Gastroenterol. 2007;42:737-745
5. Ebert EC. Gastrointestinal manifestations of Behcet’s disease. Dig Dis Sci. 2009;54:201-207
6. Cheon JH, Celik AF, Kim WHYazici Y, Yazici H. Behçet’s disease: gastrointestinal involvement. Behçet’s Syndrome. 2010 New York Springer:165-188
7. van Bodegraven AA, Mulder CJ. Indications for 5-aminosalicylate in inflammatory bowel disease: is the body of evidence complete? World J Gastroenterol. 2006;12:6115-6123
8. Sutherland L, Macdonald JK. Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev. 2006:CD000544
9. Chung MJ, Cheon JH, Kim SU, et al. Response rates to medical treatments and long-term clinical outcomes of nonsurgical patients with intestinal Behcet disease. J Clin Gastroenterol. 2010;44:e116-e122
10. Choi IJ, Kim JS, Cha SD, et al. Long-term clinical course and prognostic factors in intestinal Behcet’s disease. Dis Colon Rectum. 2000;43:692-700
11. Lee CR, Kim WH, Cho YS, et al. Colonoscopic findings in intestinal Behcet’s disease. Inflamm Bowel Dis. 2001;7:243-249
12. Cheon JH, Han DS, Park JY, et al. Development, validation, and responsiveness of a novel disease activity index for intestinal Behcet’s disease. Inflamm Bowel Dis. 2011;17:605-613
13. Prantera C, Pallone F, Brunetti G, et al. Oral 5-aminosalicylic acid (Asacol) in the maintenance treatment of Crohn’s disease. The Italian IBD Study Group. Gastroenterology. 1992;103:363-368
14. Bresci G, Petrucci A, Banti S. 5-aminosalicylic acid in the prevention of relapses of Crohn’s disease in remission: a long-term study. Int J Clin Pharmacol Res. 1991;11:200-202
15. Coated oral 5-aminosalicylic acid versus placebo in maintaining remission of inactive Crohn’s disease. Aliment Pharmacol Ther. 1990;4:55-64
16. Sutherland LR, Martin F, Bailey RJ, et al. A randomized, placebo-controlled, double-blind trial of mesalamine in the maintenance of remission of Crohn’s disease. The Canadian Mesalamine for Remission of Crohn’s Disease Study Group. Gastroenterology. 1997;112:1069-1077
17. Riley SA, Mani V, Goodman MJ, et al. Comparison of delayed-release 5-aminosalicylic acid (mesalazine) and sulfasalazine as maintenance treatment for patients with ulcerative colitis. Gastroenterology. 1988;94:1383-1389
18. Sandborn WJ, Korzenik J, Lashner B, et al. Once-daily dosing of delayed-release oral mesalamine (400-mg tablet) is as effective as twice-daily dosing for maintenance of remission of ulcerative colitis. Gastroenterology. 2010;138:1286-1296 1296 e1281-1283
19. Rasmussen SN, Lauritsen K, Tage-Jensen U, et al. 5-Aminosalicylic acid in the treatment of Crohn’s disease. A 16-week double-blind, placebo-controlled, multicentre study with Pentasa. Scand J Gastroenterol. 1987;22:877-883
20. Mahida YR, Jewell DP. Slow-release 5-amino-salicylic acid (Pentasa) for the treatment of active Crohn’s disease. Digestion. 1990;45:88-92
21. Akobeng AK, Gardener E. Oral 5-aminosalicylic acid for maintenance of medically-induced remission in Crohn’s disease. Cochrane Database Syst Rev. 2005:CD003715
22. Yazici H, Tuzun Y, Pazarli H, et al. Influence of age of onset and patient’s sex on the prevalence and severity of manifestations of Behcet’s syndrome. Ann Rheum Dis. 1984;43:783-789
23. Alpsoy E, Donmez L, Onder M, et al. Clinical features and natural course of Behcet’s disease in 661 cases: a multicentre study. Br J Dermatol. 2007;157:901-906
24. Kural-Seyahi E, Fresko I, Seyahi N, et al. The long-term mortality and morbidity of Behcet syndrome: a 2-decade outcome survey of 387 patients followed at a dedicated center. Medicine (Baltimore). 2003;82:60-76
25. Bardak Y. Effects of age and sex on Behcet’s disease. J Rheumatol. 1999;26:1008-1009
26. Yazici H, Basaran G, Hamuryudan V, et al. The ten-year mortality in Behcet’s syndrome. Br J Rheumatol. 1996;35:139-141
27. Polito JM II, Childs B, Mellits ED, et al. Crohn’s disease: influence of age at diagnosis on site and clinical type of disease. Gastroenterology. 1996;111:580-586
28. Sahmoud T, Hoctin-Boes G, Modigliani R, et al. Identifying patients with a high risk of relapse in quiescent Crohn’s disease. The GETAID Group. The Groupe d’Etudes Therapeutiques des Affections Inflammatoires Digestives. Gut. 1995;37:811-818
29. Consigny Y, Modigliani R, Colombel JF, et al. A simple biological score for predicting low risk of short-term relapse in Crohn’s disease. Inflamm Bowel Dis. 2006;12:551-557
30. Boirivant M, Leoni M, Tariciotti D, et al. The clinical significance of serum C reactive protein levels in Crohn’s disease. Results of a prospective longitudinal study. J Clin Gastroenterol. 1988;10:401-405
31. Henriksen M, Jahnsen J, Lygren I, et al. C-reactive protein: a predictive factor and marker of inflammation in inflammatory bowel disease. Results from a prospective population-based study. Gut. 2008;57:1518-1523
32. Jurgens M, John JM, Cleynen I, et al. Levels of C-reactive Protein Are Associated with Response to Infliximab Therapy in Patients with Crohn’s Disease. Clin Gastroenterol Hepatol. 2011;9:421-427 e421
33. Jung YS, Yoon JY, Lee JH, et al. Prognostic factors and long-term clinical outcomes for surgical patients with intestinal Behcet’s disease. Inflamm Bowel Dis. 2011;17:1594-1602
34. Solem CA, Loftus EV Jr., Tremaine WJ, et al. Correlation of C-reactive protein with clinical, endoscopic, histologic, and radiographic activity in inflammatory bowel disease. Inflamm Bowel Dis. 2005;11:707-712
35. Schnitzler F, Fidder H, Ferrante M, et al. Mucosal healing predicts long-term outcome of maintenance therapy with infliximab in Crohn’s disease. Inflamm Bowel Dis. 2009;15:1295-1301
36. Baert F, Moortgat L, Van Assche G, et al. Mucosal healing predicts sustained clinical remission in patients with early-stage Crohn’s disease. Gastroenterology. 2010;138:463-468; quiz e410-461
37. Yoon JY, Cheon JH, Park JJ, et al. Clinical outcomes and factors for response prediction after the first course of corticosteroid therapy in patients with active ulcerative colitis. J Gastroenterol Hepatol. 2011;26:1114-1122
38. Fujiwara S, Shimizu I, Ishikawa M, et al. Intestinal Behcet’s disease with esophageal ulcers and colonic longitudinal ulcers. World J Gastroenterol. 2006;12:2622-2624
39. Sonta T, Araki Y, Koubokawa M, et al. The beneficial effect of mesalazine on esophageal ulcers in intestinal Behcet’s disease. J Clin Gastroenterol. 2000;30:195-199
40. Yoo HM, Han KH, Kim PS, et al. Clinical features of intestinal Behcet’s disease and therapeutic effects of sulfasalazine. Korean J Gastroenterol. 1997;29:465-472